Clinical Trial Detail

NCT ID NCT02733250
Title Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Centre hospitalier de l'Université de Montréal (CHUM)
Indications

lung non-small cell carcinoma

Therapies

Nab-paclitaxel + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST